Results 41 to 50 of about 6,678 (215)

Metabolic Profiling of the EmDia Cohort by LC‐MS Reveals Empagliflozin‐Intake Associated Regulation of 1,5‐anhydroglucitol and Urate

PROTEOMICS, EarlyView.
ABSTRACT The EmDia trial, designed to study the effects of the sodium glucose cotransporter‐2 (SGLT2) inhibitor empagliflozin on cardiovascular comorbidities in type 2 diabetes mellitus (T2DM) patients, has been investigated for short‐term metabolic alterations by a limited set of clinical assays. To expand on this data, we report on the development of
Fabian Schmitt, Vincent ten Cate, Zlatka Fischer, Mathias Hagen, Barbara A. Steigenberger, Stefan Tenzer, Philipp S. Wild, Thierry Schmidlin   +7 more
wiley   +1 more source

Recent Progress in CO2 Conversion: An Overview of Catalytic Strategies for Sustainable Fuel and Chemical Synthesis

SmartMat, Volume 6, Issue 6, December 2025.
This review systematically outlines recent advances in the catalytic strategies for converting CO₂ into valuable products, including photocatalysis, electrocatalysis, CO2 hydrogenation, photothermal catalysis, non‐thermal plasma, and biocatalytic processes.
An Zhang, Yanming Cai, Liang Guo, Chao Wang, Qingbo Wa, Yanping Xu, Jian Zhou, Hongshuang Fan, Ziyun Li, Xinyue Long, Jiabei Tang, Zijian Li, Li Zhai, Zhenyu Shi, Wei Zhai, Yuhui Tian, Shuai Bi, Hao Wei, Mingliang Hu, Yang Xu, Yiran Zhang, Yu Zhang, Ruiying Ding, Junjun Li, Shuangqun Chen, Jianfeng Huang, Zhanxi Fan, Xingchen Jiao, Guigao Liu, Haiqing Wang, Haifeng Tian, Jingyu Pang, Kuncheng Zhang, Weisong Liu, Huijuan Cui, Lingling Zhang, Xiaofu Sun, Jianling Zhang, Dan Ren, Sheng Zhang, Lu Qiao, Zhe Weng, Hongmei Li, Min Liu, Miao Zhong, Lei Wang, Jun Gu, Hao Bin Wu, Bolong Huang, Weijia Zhou, Chuan Xia, Min‐Rui Gao, Changbin Zhang, Rong Cao, Wei Chen, Yuan‐Biao Huang, Yongye Liang, Ya‐Qian Lan, Guoxiong Wang, Baoyu Xia, Yujie Xiong, Xinbin Ma, Tongbu Lu, Jinhua Ye, Yi Xie, Buxing Han, Jiawei Liu, Zhicheng Zhang, Hua Zhang   +68 more
wiley   +1 more source

Management of trypanosomiasis and leishmaniasis [PDF]

, 2012
<p>Background: The current treatments for human African trypanosomiasis (HAT), Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid diseases) are far from ideal but, for some, there has been significant recent progress ...
Alsford, Alvar, Alvar, Barrett, Barrett, Ben Salah, Berman, Bern, Brun, Brun, Burri, Chappuis, Coura, Croft, Croft, El-Sayed, Frearson, Hailu, Jacobs, Jacobs, Le Loup, Lessa, M. P. Barrett, Miranda-Verastegui, Paine, Pinazo, Priotto, Rassi, Reithinger, Rodgers, S. L. Croft, Stuart, Sundar, Sundar, Sundar, Sundar, Torreele, Vanhollebeke, Vincent, Voogd   +39 more
core   +2 more sources

The Concise Guide to PHARMACOLOGY 2025/26: Transporters

British Journal of Pharmacology, Volume 182, Issue S1, Page S404-S496, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip M. Beart, Stefan Broer, Paul A. Dawson, Gergely Gyimesi, Bruno Hagenbuch, James R. Hammond, Jules C. Hancox, Michal Hershfinkel, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Edmund R. S. Kunji, Gavin Stewart, Sotiria Tavoulari, David T. Thwaites, Tiziano Verri   +28 more
wiley   +1 more source

Harnessing metabolic control for synaptic stability: REST/NRSF links glycolytic inhibition to excitatory neurotransmission

The Journal of Physiology, Volume 603, Issue 22, Page 7207-7233, November 15, 2025.
Abstract figure legend Schematic of REST/NRSF‐dependent postsynaptic downscaling of excitatory strength in response to glycolysis inhibition Glycolysis inhibition enhances REST/NRSF expression and increases REST/NRSF transcriptional repressor activity by promoting its translocation into the nucleus.
Daniele Ferrante, Barbara Parisi, Antonella Marte, Dionisi Marianna, Cosimo Prestigio, Andrea Benzi, Santina Bruzzone, Fabio Benfenati, Franco Onofri, Pierluigi Valente, Pietro Baldelli   +10 more
wiley   +1 more source

Hematological profile among cutaneous leishmaniasis patients before and after treatment with sodium stibogluconate in Diyala, Iraq

Journal of Infection in Developing Countries
Introduction: Cutaneous leishmaniasis (CL) is a common protozoan disease in Iraq characterized by localized ulcers, primarily on exposed skin. This study aimed to investigate the hematological parameters of infected patients using a complete blood count
Ghuffran Muhammed Hassan, Hayder Z Ali, Watheq Muhammed Hussein   +2 more
doaj   +1 more source

Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial [PDF]

, 2017
This randomized, open sequential design trial was set up to assess the efficacy, tolerability and toxicity of 20 d courses of combined intramuscular aminosidine and sodium stibogluconate at various dosages in patients with newly-diagnosed kala-azar in ...
Bhowmick, S., Dolfi, L., Olliaro, P., Thakur, C.P.   +3 more
core  

Farnesoid X Receptor Agonist Tropifexor Improves Intestinal Defense Response and Epithelial Barrier Function in Neonatal Piglets Receiving Parenteral Nutrition

The FASEB Journal, Volume 39, Issue 19, 15 October 2025.
Farnesoid X receptor agonist tropifexor protects against PN‐induced intestinal injury by preserving epithelial barrier integrity and enhancing mucosal defense responses, suggesting a potential prophylactic strategy for neonates requiring long‐term PN support.
Yuling Zhao, Yongtao Xiao, Lu Jiang, Ying Wang, Yang Liu, Tian Zhang, Wei Cai, Junkai Yan   +7 more
wiley   +1 more source

Antimonial Resistance in Leishmania donovani Is Associated with Increased In Vivo Parasite Burden [PDF]

, 2011
Leishmania donovani is an intracellular protozoan parasite that causes visceral leishmaniasis (VL). Antimonials (SSG) have long been the first-line treatment against VL, but have now been replaced by miltefosine (MIL) in the Indian subcontinent due to ...
AK Haldar, Ashutosh, BJ Mookerjee, CP Thakur, D Kumar, D Sereno, F Chappuis, FJ Perez-Victoria, FJ Perez-Victoria, J Hellemans, Jean-Claude Dujardin, K Seifert, K Seifert, KW Quispe Tintaya, Louis Maes, M Ouakad, M Vanaerschot, Manu Vanaerschot, Mauricio Martins Rodrigues, ML Cunningham, N Silva, N Van Meirvenne, R Lira, S Decuypere, S Rijal, S Sundar, S Wyllie, Saskia Decuypere, Simonne De Doncker, SL Croft, Suman Rijal, TK Jha, V Yardley   +32 more
core   +6 more sources

Further characterization of a secreted lipase from the human pathogen Leishmania donovani by determining the effect of various metal ions on its enzymatic activity. [PDF]

, 2014
Leishmania donovani, a protozoan parasite, is the causative agent of the often fatal disease visceral leishmaniasis. The current treatments available are minimal and toxic to the patient.
Hoertz, Lana
core   +1 more source